(Q38432853)

3 September 2017

title

Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series (English)

1 reference

inflammatory bowel diseases

3 September 2017

main subject

0 references

inflammation

0 references

author name string

Yun-Seong Kang

1

1 reference

3 September 2017

Hyoung Ho Moon

2

1 reference

3 September 2017

Seung Eun Lee

3

1 reference

3 September 2017

Yun Jeong Lim

4

1 reference

3 September 2017

Hyoun Woo Kang

5

1 reference

3 September 2017

publication date

18 October 2014

1 reference

Digestive Diseases and Sciences

3 September 2017

published in

1 reference

3 September 2017

volume

60

1 reference

3 September 2017

issue

4

1 reference

3 September 2017

page(s)

951-956

1 reference

Review article: Infliximab therapy for inflammatory bowel disease--seven years on

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3392-Z

The economic burden of TNFα inhibitors and other biologic treatments in Norway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3392-Z

Bioequivalence and the immunogenicity of biopharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3392-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3392-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3392-Z

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3392-Z

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3392-Z

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3392-Z

A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3392-Z

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3392-Z

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3392-Z

American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3392-Z

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3392-Z

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3392-Z

A critical assessment of new therapies in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3392-Z

Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3392-Z

Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3392-Z

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3392-Z

WHO Expert Committee on Biological Standardization

21 January 2018

1 reference

12 December 2020

Controlling the cost of innovative cancer therapeutics

1 reference

12 December 2020

Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study

1 reference

12 December 2020

Clinical experience with infliximab therapy in 100 patients with Crohn's disease

1 reference

12 December 2020

10.1007/S10620-014-3392-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

1053042279

0 references

1 reference